Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27055738
DOI
10.1016/j.bcp.2016.03.025
PII: S0006-2952(16)30021-1
Knihovny.cz E-zdroje
- Klíčová slova
- (RS)-warfarin alcohol (PubChem CID: 54736486), (SS)-warfarin alcohol (PubChem CID: 56842683), Aldo–keto reductase (AKR), Carbonyl reducing enzymes, Carbonyl reductase (CBR), Drug metabolism, Short-chain dehydrogenase/reductase, Warfarin, Warfarin (PubChem CID: 54678486), Warfarin alcohol (PubChem CID: 54712717),
- MeSH
- 3-hydroxysteroid dehydrogenasy metabolismus MeSH
- aldehydreduktasa metabolismus MeSH
- alkoholoxidoreduktasy metabolismus MeSH
- antikoagulancia metabolismus MeSH
- biotransformace MeSH
- Escherichia coli genetika metabolismus MeSH
- exprese genu MeSH
- hydroxyprostaglandindehydrogenasy metabolismus MeSH
- izoenzymy metabolismus MeSH
- jaterní mikrozomy enzymologie MeSH
- játra enzymologie MeSH
- kinetika MeSH
- kultivační média chemie MeSH
- lidé MeSH
- oxidace-redukce MeSH
- protein AKR1C3 MeSH
- rekombinantní proteiny metabolismus MeSH
- stereoizomerie MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- warfarin metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- 3-hydroxysteroid dehydrogenasy MeSH
- AKR1A1 protein, human MeSH Prohlížeč
- AKR1B1 protein, human MeSH Prohlížeč
- AKR1C3 protein, human MeSH Prohlížeč
- aldehydreduktasa MeSH
- alkoholoxidoreduktasy MeSH
- antikoagulancia MeSH
- CBR1 protein, human MeSH Prohlížeč
- hydroxyprostaglandindehydrogenasy MeSH
- izoenzymy MeSH
- kultivační média MeSH
- protein AKR1C3 MeSH
- rekombinantní proteiny MeSH
- warfarin MeSH
Warfarin is a widely used anticoagulant and, unfortunately, is a drug that is commonly implicated in serious adverse events including fatalities. Although several factors, including the metabolism of warfarin via CYP450, have been reported to affect the safety and efficacy of warfarin therapy, the wide variance in the warfarin dosage in patients has not been completely clarified. In addition to the oxidative metabolism of warfarin mediated by CYP450, reductive metabolism is involved in warfarin biotransformation. However, the reductive metabolism of warfarin has been largely unexplored and deserves further investigation. We studied warfarin reduction by human liver fractions and found a 9-fold higher velocity of warfarin reduction in the cytosol than in microsomes (Vmax=77.2 vs. 8.7pmol/mgprotein/min, respectively). Furthermore, of nine recombinant cytosolic carbonyl reducing enzymes tested for their ability to reduce warfarin, AKR1C3 and CBR1 were identified as warfarin reductases and their kinetic parameters were determined. The internal clearance of warfarin was 3 orders of magnitude higher with AKR1C3 than with CBR1 (CLint=65.922 vs. 0.070μl/mgprotein/min, respectively). This is the first time that warfarin reducing enzymes in human liver subcellular fraction have been identified. Moreover, we have described the chiral aspects of warfarin reduction using an HPLC method that enabled the detection of individual warfarin alcohol stereoisomers. Cytosol and AKR1C3 exhibit the stereoselective metabolism of (R)-warfarin to preferentially form (SR)-warfarin alcohol as the primary in vivo metabolite of warfarin. On the other hand, microsomes and CBR1 preferentially reduce (S)-warfarin to form (RS)-warfarin alcohol and (SS)-warfarin alcohol, respectively.
Citace poskytuje Crossref.org